Navigation Links
Novel approach to treat proliferative vitreoretinopathy shows promise
Date:10/30/2011

Philadelphia, PA -- Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

"We found that a combination of 7 classes of growth factors and cytokines was essential for PVR to develop in an animal model of the disease," explains lead investigator Andrius Kazlauskas, PhD, of The Schepens Eye Research Institute and the Department of Ophthalmology, Harvard Medical School. "By neutralizing them, we prevented PVR-relevant signaling, and inhibited contraction of collagen gels containing primary retinal pigment epithelial cells derived from a human PVR membrane (RPEMs). These findings suggest a potential therapeutic approach to reduce the incidence of PVR in patients undergoing surgery to repair a detached retina."

In animal models, platelet-derived growth factor receptor α (PDGFRα) is associated with PVR and strongly promotes experimental PVR. Vitreal growth factors outside of the PDGF family promote an indirect route to activate PDGFRα. Importantly, indirectly activated PDGFRα engages a characteristic set of signaling events and cellular responses that are tightly associated with PVR. This study sought to identify the factors that would induce those events, and develop therapeutic approaches to prevent patients from developing PVR.

Vitreous was obtained from normal rabbits or those in which PVR was either developing or stabilized. Normal vitreous was found to contain substantial levels of growth factors and cytokines, which change quantitatively or qualitatively as PVR develops. A set of nine growth agents was found to be most abundant and therefore most likely to contribute to PVR. Neutralizing a subset of these factors in rabbit vitreous eliminated their ability to induce PVR-relevant signaling and cellular responses. A single dose of neutralizing reagents effectively protected rabbits from developing retinal detachment. "Our in vitro approach to characterize and neutralize vitreal bioactivity accurately predicted the efficacy of an in vivo therapy," notes Dr. Kazlauskas.

To identify growth factors likely to be driving PVR in humans, the investigators quantified the level of growth factors and cytokines from human donors that had either PVR, or a non-PVR retinal condition. Fourteen of the 24 agents quantified were present in large concentrations in PVR vitreous. Neutralizing just 7 of these prevented vitreous-induced activation of PDGFRα. Furthermore, the cocktail also suppressed the contraction of these cells in collagen. Therefore, the same neutralization strategy that prevented PVR in rabbits also prevented human PVR vitreous from inducing PVR-relevant responses. These results strongly suggest that a dose of neutralizing reagents may also protect humans from PVR.

"Although the outlook is encouraging, it would be useful to test the effectiveness of this treatment on alternate models of retinal detachment. It is also worth considering a combinatorial approach to therapy. For example, the antioxidant N-acetylcysteine (NAC) prevents retinal detachment in rabbits by blocking intracellular processes. A combined therapy involving the neutralization approach presented here with NAC treatment would doubly-target PVR at the extracellular and intracellular levels," concludes Dr. Kazlauskas.


'/>"/>
Contact: David Sampson
ajpmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Novel strategy stymies SARS et al.
2. Novel therapeutic target identified to decrease triglycerides and increase good cholesterol
3. Innovation at Regenstrief: Leveraging novel ideas to improve health care
4. Novel technique reveals both gene number and protein expression simultaneously
5. Novel research set to pinpoint risk of heart attacks and strokes
6. Novel cytokine protects mice from colitis
7. FDA Approves Novel Melanoma Drug
8. St. Michaels North America first to use novel blood-cleaning procedure for kidney transplant
9. Novel DNA sequencer for MDCs systems biology
10. Novel Virus Jumped From Monkeys to Humans, Researchers Find
11. Novel combined therapy extends life, diminishes pain in brain cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , Dr. ... care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for ... at risk for serious complications and often experience severe pain. Not only does ...
(Date:2/20/2017)... ... , ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) ... Cheese’s locations throughout New England, New York and New Jersey to provide children with ... of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After a successful ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that ... gift was facilitated by the Pepin Family Foundation. , “We greatly appreciate this ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating ... Exposition, the event will take place February 23-25, 2017 at the Calvin L. Rampton ... Booth #909 with three new ambulances on display. , “JEMS is ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... ... proven to result in better care, and MEDfx and the Delaware Health Information ... of Delaware. , As the nation’s first state-wide health information exchange, DHIN stores ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)...   AC Group Inc. , a leading company, ... in the PMS/EHR healthcare marketplace, will exhibit the 7 ... succeed in this ecosystem at HIMSS,17. ... from over 200 ACOs, compared and analyzed an ACO,s ... that are providing different pieces of Population Health technologies ...
(Date:2/18/2017)... , Feb. 17, 2017   Parker ... protecting the rights of victims injured by medical ... regulators to call for better reporting. Congress required ... Safety concerns involving power morcellators and duodenoscopes ... to investigate how hospitals report injuries and deaths ...
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
Breaking Medicine Technology: